Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Obiltoxaximab
Drug ID BADD_D01593
Description Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
Indications and Usage Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.
Marketing Status approved
ATC Code J06BC04
DrugBank ID DB05336
KEGG ID D10776
MeSH ID C000611266
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 69604-204; 67643-0018
UNII 29Z5DNL48C
Synonyms obiltoxaximab | ETI-204 | Anthim
Chemical Information
Molecular Formula Not Available
CAS Registry Number 1351337-07-9
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood creatine phosphokinase increased13.04.01.001--
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.002---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Cough22.02.03.001--
Cyanosis02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.007--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Fatigue08.01.01.002--
Headache17.14.01.001--
Lymphocyte count decreased13.01.06.006--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Neutrophil count decreased13.01.06.010--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rhinorrhoea22.12.03.021--
Sinus congestion22.04.06.001---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.003--
White blood cell count decreased13.01.06.012--
Injection site discolouration08.02.03.038; 12.07.03.038; 23.03.03.046---
Infusion site pain08.02.05.014; 12.07.05.002---
Infusion site swelling08.02.05.002; 12.07.05.003---
Vessel puncture site bruise08.02.04.009; 12.07.04.009; 23.03.11.014; 24.07.06.016---
The 1th Page    1 2    Next   Last    Total 2 Pages